Comment from CIMS Global
AnonymousSupportBusiness
Summary: CIMS Global is submitting a high-level overview of its capabilities and ready-to-implement solutions regarding AI-enabled optimization in early-phase clinical trials. They express support for the FDA's initiative and offer to provide additional technical materials to help advance clinical trial innovation.
CONFIDENTIAL- CIMS Global's submission provides a high-level overview of our capabilities and key considerations relevant to FDA's RFI on the AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program (Docket No. FDA-2026-N-4390). The attached submission highlights our ready-to-implement solutions designed to accelerate early phase clinical trials. Additional details and technical materials are provided through FDA's confidential submission process. We thank the FDA for this opportunity to contribute to this critical discussion and look forward to supporting the advancement of clinical trial innovation.